Sign In
Step 1
Draft
Step 2
Unite with Fellow Investors
Step 3
Choose the Best Attorney
Step 4
Provide Documents
Step 5
Follow Case Progress
Step 6
Get Payout
AXSM.US
id: 1736

Axsome Therapeutics ($AXSM) $7.75M Investor Settlement

Late claims are being considered for compensation, subject to approval.
$7,750,000
Cash Settlement
S.D. New York
Court
1:22-cv-03925
Case number
05/10/2021
Class period Start
04/22/2022
Class period End
02/03/2026
Claim deadline
Axsome Therapeutics has agreed to a $7.75 million settlement with $AXSM investors to resolve claims that it misled them about regulatory risks related to the company’s migraine drug AXS-07.
Case Type
US Securities Class Action
Case Status
Accepting Late Claims
Alleged Offence
Misleading Statements
Financial Misrepresentation
Failure to Disclose
Suspected Party
Management
Security Type
Stocks
Trade Direction
Long
Payout per Share
0.46
Filing date
05/13/2022
Plaintiffs
Evy Gru
Attorneys
Pomerantz LLP
Defendants
Herriot Tabuteau; Nick Pizzie; Mark Jacobson; Cedric O’Gorman
Administrator
Strategic Claims Services
Court hearing date
02/10/2026
Exclusion deadline
01/13/2026
Objection deadline
01/13/2026
Attorney fee
$2,733,333
Trades matching type
FIFO

Frequently Asked Questions

Trusted by industry leaders

Endorsed by top professionals who trust our innovative solutions to drive impactful results.